PPAR-γ Agonists As Antineoplastic Agents in Cancers with Dysregulated IGF Axis

PPAR-γ Agonists As Antineoplastic Agents in Cancers with Dysregulated IGF Axis

It is now widely accepted that insulin resistance and compensatory hyperinsulinemia are associated to increased cancer incidence and mortality. Moreover, cancer development and progression as well as cancer resistance to traditional anticancer therapies are often linked to a deregulation/overactivation of the insulin-like growth factor (IGF) axis, which involves the autocrine/paracrine producti...

Novel Therapeutic Agents in Pediatric Sepsis: Peroxisome Proliferator Receptor γ (PPAR γ) Agonists.

Sepsis is characterized by a systemic inflammatory response. Systemic physiologic changes can occur and lead to cellular damage and organ failure. The nuclear receptor, peroxisome proliferator-activated receptor(PPAR ), is involved in the regulation of the inflammatory response and is altered in sepsis. Thiazolidinediones (TZDs), and the cyclopentenone prostaglandin, 15d-PGJ2, are specific PPAR...

Development of Ppar-γ Receptor Agonists as Therapeutic Agents for Diabetes

Diabetes Mellitus: Recent Advancement in Ppar Agonists as Therapeutic Agents

Diabetes mellitus is known as metabolic disorder related to glucose intolerance which is characterized by hyperglycemia. Diabetes mellitus can be treated by insulin and oral hypoglycemic agents. Most of known oral hypoglycemic are peroxisome proliferatoractivated receptors (PPAR) agonist. There are three different subtypes of PPARs are identified and they are involved in glucose metabolism. A b...

PPAR-γ Agonists and Their Effects on IGF-I Receptor Signaling: Implications for Cancer

It is now well established that the development and progression of a variety of human malignancies are associated with dysregulated activity of the insulin-like growth factor (IGF) system. In this regard, promising drugs have been developed to target the IGF-I receptor or its ligands. These therapies are limited by the development of insulin resistance and compensatory hyperinsulinemia, which i...